

Dr. Jim Chiarotto

Regional Systemic Therapy Lead

Biography

Dr. Jim Chiarotto is the Regional Systemic Therapy (Chemotherapy) Lead for the Central East Regional Cancer Program. Dr. Chiarotto is currently a medical oncologist at Scarborough Health Network (SHN), where he has cared for patients at the Centenary Site since 2002.

Dr. Chiarotto received his medical degree from the University of Toronto (U of T) and his internal medicine training at Queen's University. He completed his training in medical oncology at McGill University before returning to U of T to complete a Masters Degree in Molecular Biology and Cancer Research. He is certified in medical oncology by the Royal College of Physicians and Surgeons and the American Board of Internal Medicine. Dr. Chiarotto first practiced medical oncology at Lakeridge Health Oshawa from 1998-2002.

He then joined the team at SHN. His team was awarded the Cancer Care Ontario Human Touch Award and he was awarded the Top of the Valley Award for contributions to SHN.

While at the Scarborough Health Network he has published work in the field of breast cancer, colon cancer, and exercise for cancer patients, and is currently working on improving patient comprehension.

Topics

- Breast Cancer Treatment
 - Colorectal Cancer Treatment
-

Availability

- Keynote
 - Moderator
 - Panelist
 - Workshop Leader
 - Host or MC
-

Recent Presentations

- Durham Regional Cancer Centre, Lakeridge Health 2012. "Myeloma/Leukemia". 5 Chiefs Family Medicine Clinic Day.
- Rouge Valley Health System 2010. "Cancer and the Elderly". Cancer Care Educational Update.

- ACNP Educational Evening 2009. "Everything You Wanted to Know About Breast Cancer".
 - Rouge Valley Health System 2008. "An Update on the Management of Rectal Cancer". General Surgeon's Educational Rounds.
-

Research

Publications

- Santa Mina D, Sabiston CM, Au D, Fong AJ, Capozzi LC, Langelier D, Chasen M, Chiarotto J, Tomasone JR, Jones JM, Chang E, Culos-Reed SN. "Connecting People With Cancer To Physical Activity And Exercise Programs: A Pathway To Create Accessibility And Engagement", *Current Oncology* (2018) 25(2): 149-162.
- Chiarotto, J.A., Akbarali, R., Bellotti, L., Dranitsaris, G., "A Structured Group Exercise Program For Patients With Metastatic Cancer Receiving Chemotherapy And Ctnnb1 (B-Catenin) As A Marker Of Exercise Efficacy." *Cancer Management and Research* (2017) 9: 495-501.
- Chiarotto, J.A., Dranitsaris, G., "Folfox Chemotherapy Can Safely Be Given To Neutropenic Patients With Early Stage Colorectal Cancer For Higher Dose Intensity And Fewer Visits." *Supportive Care in Cancer* (2016) 24: 2533-2539.
- Chiarotto, J.A., Dranitsaris, G., "Full-Dose Chemotherapy In Early Stage Breast Cancer Regardless Of Absolute Neutrophil Count And Without G-CSF Does Not Increase Chemotherapy-Induced Febrile Neutropenia." *Supportive Care in Cancer* (2013), 21: 2727-2731.
- West, P.J, Chiarotto, J. A. Et al, "Nurse-Initiated Chemo Saves Chairs and Wins Smiles." 14th International Conference on Cancer Nursing, 27 Sep-01 Oct 2006.
- Chiarotto, J.A., Hill, R., "The Expression Of Vascular Endothelial Growth Factor In Cervical Cancer Cells As A Function Of Oxygen Tension." *Proceedings of the 89th Annual Meeting of the American Association for Cancer Research, New Orleans, USA. March 1998, 39:377.*
- Chiarotto, J.A., Wainer, I., "Metyrapone As A Prochiral Probe Of Cytoplasmic Aldo-Keto Reductase Activity.", 12th International Congress of Pharmacology, Montreal, Canada. July 1994.

- Chiarotto, J.A., Thirlwell, M., Trudeau, M. et al, "Phase I-II Trial Of An Unconventional Agent, Polyerga, In Patients With Advanced Cancer." *Clinical Research*, Feb 1994, 42(1): p 104A.

Papers

1. Chiarotto, J.A., Dranitsaris, G., "Full-Dose Chemotherapy In Early Stage Breast Cancer Regardless Of Absolute Neutrophil Count And Without G-Csf Does Not Increase Chemotherapy-Induced Febrile Neutropenia.", *Supportive Care in Cancer* (2013),21, 2727-2731.
2. Chiarotto,J.A., Hill,R.P., "A Quantitative Analysis Of The Reduction In Oxygen Levels Required To Induce Upregulation Of Vegf mRNA Levels In Cervical Cancer Cell Lines.", *British Journal of Cancer* (1999), 80, 1518-1524.
3. Chiarotto,J.A., Wainer,I., "Determination Of Metyrapone And The Enantiomers Of Its Chiral Metabolite Metyrapol In Plasma And Urine Using Coupled Achiral/Chiral Liquid Chromatography." *Journal of Chromatography B*, 665 (1995),147-154.
4. Chiarotto,J.A., Wainer,I., "Enantiospecificity Of The Aldo-Keto Reductase-Mediated Reduction Of Metyrapone In Volunteers: An Initial Observation Of An Inter-Individual Difference." *Pharmaceutical Sciences* 1995, 1: 79-80.